175 related articles for article (PubMed ID: 34063871)
1. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
[TBL] [Abstract][Full Text] [Related]
2. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
Aves KL; Sander AF
Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
[TBL] [Abstract][Full Text] [Related]
3. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
[TBL] [Abstract][Full Text] [Related]
4. Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.
Kang H; Martinez MR; Aves KL; Okholm AK; Wan H; Chabot S; Malik T; Sander AF; Daniels R
iScience; 2024 Jun; 27(6):110038. PubMed ID: 38883830
[TBL] [Abstract][Full Text] [Related]
5. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
6. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
7. A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines.
Goksøyr L; Skrzypczak M; Sampson M; Nielsen MA; Salanti A; Theander TG; Remaley AT; De Jongh WA; Sander AF
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679847
[TBL] [Abstract][Full Text] [Related]
8. Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
Aves KL; Janitzek CM; Fougeroux CE; Theander TG; Sander AF
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745873
[TBL] [Abstract][Full Text] [Related]
9. Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells.
Fausch SC; Da Silva DM; Kast WM
Vaccine; 2005 Feb; 23(14):1720-9. PubMed ID: 15705478
[TBL] [Abstract][Full Text] [Related]
10. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
[TBL] [Abstract][Full Text] [Related]
11. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
12. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.
Da Silva DM; Schiller JT; Kast WM
Vaccine; 2003 Jul; 21(23):3219-27. PubMed ID: 12804851
[TBL] [Abstract][Full Text] [Related]
13. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.
Aves KL; Goksøyr L; Sander AF
Viruses; 2020 Feb; 12(2):. PubMed ID: 32041299
[TBL] [Abstract][Full Text] [Related]
14. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
15. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers.
Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Soerensen A; Jørgensen T; Clemmensen S; Soroka V; Thrane S; Theander T; Nielsen MA; Salanti A; Bukh J; Sander AF
NPJ Vaccines; 2022 Nov; 7(1):148. PubMed ID: 36379958
[TBL] [Abstract][Full Text] [Related]
16. Optimization of a Soft Ensemble Vote Classifier for the Prediction of Chimeric Virus-Like Particle Solubility and Other Biophysical Properties.
Vormittag P; Klamp T; Hubbuch J
Front Bioeng Biotechnol; 2020; 8():881. PubMed ID: 32850736
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types.
Chen X; Liu H; Wang Z; Wang S; Zhang T; Hu M; Qiao L; Xu X
Oncotarget; 2017 Sep; 8(38):63333-63344. PubMed ID: 28968993
[TBL] [Abstract][Full Text] [Related]
18. Display of Streptococcus iniae α-Enolase on the Surface of Virus-Like Particles (VLPs) of Nervous Necrosis Virus (NNV) Using SpyTag/SpyCatcher.
Yang JI; Kim KH
Mar Biotechnol (NY); 2022 Dec; 24(6):1066-1072. PubMed ID: 36171522
[TBL] [Abstract][Full Text] [Related]
19. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
20. Influenza virus-like particles composed of conserved influenza proteins and GPI-anchored CCL28/GM-CSF fusion proteins enhance protective immunity against homologous and heterologous viruses.
Liu J; Ren Z; Wang H; Zhao Y; Wilker PR; Yu Z; Sun W; Wang T; Feng N; Li Y; Wang H; Ji X; Li N; Yang S; He H; Qin C; Gao Y; Xia X
Int Immunopharmacol; 2018 Oct; 63():119-128. PubMed ID: 30081250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
